{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:30:36Z","timestamp":1790692236727,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Sichuan Science and Technology Program","award":["2024ZYD0064"],"award-info":[{"award-number":["2024ZYD0064"]}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","award":["ZYYC20002"],"award-info":[{"award-number":["ZYYC20002"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08036-x","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T04:05:10Z","timestamp":1774497910000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["MMP14 is a safe target of CAR-T therapy against liver cancer and metastasis"],"prefix":"10.1186","volume":"24","author":[{"given":"Ye","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirui","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqiong","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"8036_CR1","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics. 2023. CA Cancer J Clin. 2023;73(1):17\u201348. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36633525.","DOI":"10.3322\/caac.21763"},{"issue":"1","key":"8036_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33479224.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"8036_CR3","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.hoc.2022.03.006","volume":"36","author":"G Ottaviano","year":"2022","unstructured":"Ottaviano G, Qasim W, Genome-Edited T, Cell Therapies. Hematol Oncol Clin North Am. 2022;36(4):729\u201344. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35773047.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"8036_CR4","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1172\/JCI129208","volume":"130","author":"MJ Frigault","year":"2020","unstructured":"Frigault MJ, Maus MV. State of the art in CAR T cell therapy for CD19\u2009+\u2009B cell malignancies. J Clin Invest. 2020;130(4):1586\u201394. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32235098.","journal-title":"J Clin Invest"},{"key":"8036_CR5","doi-asserted-by":"crossref","unstructured":"Haslauer T, Greil R, Zaborsky N, Geisberger R. CAR T-Cell Therapy in Hematological Malignancies. Int J Mol Sci 2021;22(16). https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34445701","DOI":"10.3390\/ijms22168996"},{"issue":"15","key":"8036_CR6","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","volume":"26","author":"D Shi","year":"2020","unstructured":"Shi D, Shi Y, Kaseb AO, Qi X, Zhang Y, Chi J, et al. Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials. Clin Cancer Res. 2020;26(15):3979\u201389. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32371538.","journal-title":"Clin Cancer Res"},{"key":"8036_CR7","doi-asserted-by":"publisher","first-page":"824208","DOI":"10.3389\/fonc.2022.824208","volume":"12","author":"X Zheng","year":"2022","unstructured":"Zheng X, Liu X, Lei Y, Wang G, Liu M. Glypican-3: A novel and promising target for the treatment of hepatocellular carcinoma. Front Oncol. 2022;12:824208. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35251989.","journal-title":"Front Oncol"},{"issue":"1","key":"8036_CR8","doi-asserted-by":"publisher","first-page":"1846926","DOI":"10.1080\/2162402X.2020.1846926","volume":"9","author":"H Dai","year":"2020","unstructured":"Dai H, Tong C, Shi D, Chen M, Guo Y, Chen D, et al. Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial. Oncoimmunology. 2020;9(1):1846926. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33312759.","journal-title":"Oncoimmunology"},{"issue":"5","key":"8036_CR9","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1158\/0008-5472.CAN-07-6013","volume":"68","author":"T Yamashita","year":"2008","unstructured":"Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008;68(5):1451\u201361. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18316609.","journal-title":"Cancer Res"},{"issue":"3","key":"8036_CR10","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.immuni.2004.06.018","volume":"21","author":"S Hue","year":"2004","unstructured":"Hue S, Mention JJ, Monteiro RC, Zhang S, Cellier C, Schmitz J, et al. A direct role for NKG2D\/MICA interaction in villous atrophy during celiac disease. Immunity. 2004;21(3):367\u201377. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15357948.","journal-title":"Immunity"},{"issue":"11","key":"8036_CR11","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1158\/2326-6066.CIR-19-0026","volume":"7","author":"B Sun","year":"2019","unstructured":"Sun B, Yang D, Dai H, Liu X, Jia R, Cui X, et al. Eradication of hepatocellular carcinoma by NKG2D-based CAR-T cells. Cancer Immunol Res. 2019;7(11):1813\u201323. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31484657.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"8036_CR12","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1158\/1078-0432.CCR-16-1203","volume":"23","author":"H Liu","year":"2017","unstructured":"Liu H, Xu Y, Xiang J, Long L, Green S, Yang Z, et al. Targeting alpha-fetoprotein (AFP)-MHC complex with CAR T-Cell therapy for liver cancer. Clin Cancer Res. 2017;23(2):478\u201388. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27535982.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"8036_CR13","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","volume":"20","author":"AJ Hou","year":"2021","unstructured":"Hou AJ, Chen LC, Chen YY. Navigating CAR-T cells through the solid-tumour microenvironment. Nat Rev Drug Discov. 2021;20(7):531\u201350. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33972771.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"8036_CR14","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1161\/01.RES.0000070112.80711.3D","volume":"92","author":"R Visse","year":"2003","unstructured":"Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92(8):827\u201339. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12730128.","journal-title":"Circ Res"},{"key":"8036_CR15","doi-asserted-by":"crossref","unstructured":"Turunen SP, Tatti-Bugaeva O, Lehti K. Membrane-type matrix metalloproteases as diverse effectors of cancer progression. Biochim Biophys Acta Mol Cell Res. 2017;1864(11 Pt A):1974\u201388. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28390905.","DOI":"10.1016\/j.bbamcr.2017.04.002"},{"issue":"40","key":"8036_CR16","doi-asserted-by":"publisher","first-page":"6269","DOI":"10.3748\/wjg.v11.i40.6269","volume":"11","author":"YC Ip","year":"2005","unstructured":"Ip YC, Cheung ST, Leung KL, Fan ST. Mechanism of metastasis by membrane type 1-matrix metalloproteinase in hepatocellular carcinoma. World J Gastroenterol. 2005;11(40):6269\u201376. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16419154.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"8036_CR17","first-page":"5020","volume":"15","author":"D Di","year":"2018","unstructured":"Di D, Chen L, Guo Y, Wang L, Wang H, Ju J. Association of BCSC-1 and MMP-14 with human breast cancer. Oncol Lett. 2018;15(4):5020\u20136. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29552138.","journal-title":"Oncol Lett"},{"issue":"1","key":"8036_CR18","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/1475-2867-13-98","volume":"13","author":"G Yao","year":"2013","unstructured":"Yao G, He P, Chen L, Hu X, Gu F. MT1-MMP in breast cancer: induction of VEGF-C correlates with metastasis and poor prognosis. Cancer Cell Int. 2013;13(1):98. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24119788.","journal-title":"Cancer Cell Int"},{"issue":"3","key":"8036_CR19","first-page":"150","volume":"16","author":"DA Fishman","year":"1996","unstructured":"Fishman DA, Bafetti LM, Stack MS. Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells. Invasion Metastasis. 1996;16(3):150\u20139. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9186550.","journal-title":"Invasion Metastasis"},{"issue":"4","key":"8036_CR20","doi-asserted-by":"publisher","first-page":"372","DOI":"10.21873\/cgp.20327","volume":"19","author":"UH Weidle","year":"2022","unstructured":"Weidle UH, Birzele F. Long non-coding RNAs with in vitro and in vivo efficacy in preclinical models of esophageal squamous cell carcinoma which act by a Non-microRNA sponging mechanism. Cancer Genomics Proteom. 2022;19(4):372\u201389. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35732324.","journal-title":"Cancer Genomics Proteom"},{"issue":"5","key":"8036_CR21","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.ccell.2017.10.001","volume":"32","author":"AT Nguyen","year":"2017","unstructured":"Nguyen AT, Chia J, Ros M, Hui KM, Saltel F, Bard F. Organelle specific O-Glycosylation drives MMP14 activation, tumor growth, and metastasis. Cancer Cell. 2017;32(5):639\u201353.e6. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29136507.","journal-title":"Cancer Cell"},{"issue":"1","key":"8036_CR22","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1186\/s12885-018-4744-4","volume":"18","author":"JJ Yu","year":"2018","unstructured":"Yu JJ, Xiao W, Dong SL, Liang HF, Zhang ZW, Zhang BX, et al. Effect of surgical liver resection on circulating tumor cells in patients with hepatocellular carcinoma. BMC Cancer. 2018;18(1):835. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30126375.","journal-title":"BMC Cancer"},{"issue":"9","key":"8036_CR23","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1158\/0008-5472.CAN-11-4149","volume":"72","author":"AG Remacle","year":"2012","unstructured":"Remacle AG, Golubkov VS, Shiryaev SA, Dahl R, Stebbins JL, Chernov AV, et al. Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth. Cancer Res. 2012;72(9):2339\u201349. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22406620.","journal-title":"Cancer Res"},{"issue":"8","key":"8036_CR24","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1074\/jbc.M116.756718","volume":"292","author":"V Arkadash","year":"2017","unstructured":"Arkadash V, Yosef G, Shirian J, Cohen I, Horev Y, Grossman M, et al. Development of high affinity and high specificity inhibitors of matrix metalloproteinase 14 through computational design and directed evolution. J Biol Chem. 2017;292(8):3481\u201395. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28087697.","journal-title":"J Biol Chem"},{"issue":"4","key":"8036_CR25","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1158\/0008-5472.CAN-08-3255","volume":"69","author":"L Devy","year":"2009","unstructured":"Devy L, Huang L, Naa L, Yanamandra N, Pieters H, Frans N, et al. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res. 2009;69(4):1517\u201326. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19208838.","journal-title":"Cancer Res"},{"issue":"24","key":"8036_CR26","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.4161\/cbt.8.24.10139","volume":"8","author":"J Suojanen","year":"2009","unstructured":"Suojanen J, Salo T, Koivunen E, Sorsa T, Pirila E. A novel and selective membrane type-1 matrix metalloproteinase (MT1-MMP) inhibitor reduces cancer cell motility and tumor growth. Cancer Biol Ther. 2009;8(24):2362\u201370. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19855192.","journal-title":"Cancer Biol Ther"},{"issue":"49","key":"8036_CR27","doi-asserted-by":"publisher","first-page":"35126","DOI":"10.1074\/jbc.M113.496067","volume":"288","author":"AM Woskowicz","year":"2013","unstructured":"Woskowicz AM, Weaver SA, Shitomi Y, Ito N, Itoh Y. MT-LOOP-dependent localization of membrane type I matrix metalloproteinase (MT1-MMP) to the cell adhesion complexes promotes cancer cell invasion. J Biol Chem. 2013;288(49):35126\u201337. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24165131.","journal-title":"J Biol Chem"},{"issue":"2","key":"8036_CR28","doi-asserted-by":"publisher","first-page":"101","DOI":"10.4155\/bio-2020-0256","volume":"13","author":"C Gowland","year":"2021","unstructured":"Gowland C, Berry P, Errington J, Jeffrey P, Bennett G, Godfrey L, et al. Development of a LC-MS\/MS method for the quantification of toxic payload DM1 cleaved from BT1718 in a Phase I study. Bioanalysis. 2021;13(2):101\u201313. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33496610.","journal-title":"Bioanalysis"},{"issue":"1","key":"8036_CR29","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s40425-019-0642-9","volume":"7","author":"D Yang","year":"2019","unstructured":"Yang D, Sun B, Dai H, Li W, Shi L, Zhang P, et al. T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells. J Immunother Cancer. 2019;7(1):171. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31288857.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"8036_CR30","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","volume":"13","author":"L Chen","year":"2013","unstructured":"Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227\u201342. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23470321.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"8036_CR31","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","volume":"25","author":"Z Ying","year":"2019","unstructured":"Ying Z, Huang XF, Xiang X, Liu Y, Kang X, Song Y, et al. A safe and potent anti-CD19 CAR T cell therapy. Nat Med. 2019;25(6):947\u201353. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31011207.","journal-title":"Nat Med"},{"issue":"12","key":"8036_CR32","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/nrc1232","volume":"3","author":"R Pardal","year":"2003","unstructured":"Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer. 2003;3(12):895\u2013902. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/14737120.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"8036_CR33","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.18632\/aging.204021","volume":"14","author":"Y Pan","year":"2022","unstructured":"Pan Y, Fan Y, Lu Y, Peng S, Lin H, Deng Q. Molecular characterization of matrix metalloproteinase gene family across primates. Aging. 2022;14(8):3425\u201345. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35444067.","journal-title":"Aging"},{"key":"8036_CR34","doi-asserted-by":"crossref","unstructured":"Puerto-Camacho P, Diaz-Martin J, Olmedo-Pelayo J, Bolado-Carrancio A, Salguero-Aranda C, Jordan-Perez C, et al. Endoglin and MMP14 contribute to ewing sarcoma spreading by modulation of cell-matrix interactions. Int J Mol Sci 2022;23(15). https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35955799","DOI":"10.3390\/ijms23158657"},{"issue":"6","key":"8036_CR35","doi-asserted-by":"publisher","first-page":"8381","DOI":"10.1002\/jcp.27740","volume":"234","author":"M Najafi","year":"2019","unstructured":"Najafi M, Farhood B, Mortezaee K. Cancer stem cells (CSCs) in cancer progression and therapy. J Cell Physiol. 2019;234(6):8381\u201395. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30417375.","journal-title":"J Cell Physiol"},{"issue":"1","key":"8036_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12964-020-00627-5","volume":"19","author":"Y Li","year":"2021","unstructured":"Li Y, Wang Z, Ajani JA, Song S. Drug resistance and cancer stem cells. Cell Commun Signal. 2021;19(1):19. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33588867.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"8036_CR37","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41392-020-0110-5","volume":"5","author":"L Yang","year":"2020","unstructured":"Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020;5(1):8. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32296030.","journal-title":"Signal Transduct Target Ther"},{"key":"8036_CR38","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.3389\/fimmu.2020.01280","volume":"11","author":"L Walcher","year":"2020","unstructured":"Walcher L, Kistenmacher AK, Suo H, Kitte R, Dluczek S, Strauss A, et al. Cancer Stem cells-origins and biomarkers: perspectives for targeted personalized therapies. Front Immunol. 2020;11:1280. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32849491.","journal-title":"Front Immunol"},{"key":"8036_CR39","doi-asserted-by":"crossref","unstructured":"Skurikhin EG, Ermakova N, Zhukova M, Pershina O, Pan E, Pakhomova A, et al. Analysis of circulating tumor and cancer stem cells provides new opportunities in diagnosis and treatment of small cell lung cancer. Int J Mol Sci 2022;23(18). https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36142766","DOI":"10.3390\/ijms231810853"},{"key":"8036_CR40","doi-asserted-by":"publisher","first-page":"1098445","DOI":"10.3389\/fimmu.2022.1098445","volume":"13","author":"M Vyas","year":"2022","unstructured":"Vyas M, Requesens M, Nguyen TH, Peigney D, Azin M, Demehri S. Natural killer cells suppress cancer metastasis by eliminating circulating cancer cells. Front Immunol. 2022;13:1098445. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36733396.","journal-title":"Front Immunol"},{"key":"8036_CR41","doi-asserted-by":"publisher","first-page":"120224","DOI":"10.1016\/j.biomaterials.2020.120224","volume":"257","author":"K Wang","year":"2020","unstructured":"Wang K, Ye H, Zhang X, Wang X, Yang B, Luo C, et al. An exosome-like programmable-bioactivating paclitaxel prodrug nanoplatform for enhanced breast cancer metastasis inhibition. Biomaterials. 2020;257:120224. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32736255.","journal-title":"Biomaterials"},{"issue":"9","key":"8036_CR42","doi-asserted-by":"publisher","first-page":"2101472","DOI":"10.1002\/advs.202101472","volume":"9","author":"W Mu","year":"2022","unstructured":"Mu W, Chu Q, Yang H, Guan L, Fu S, Gao T, et al. Multipoint costriking nanodevice eliminates primary tumor cells and associated-circulating tumor cells for enhancing metastasis inhibition and therapeutic effect on HCC. Adv Sci (Weinh). 2022;9(9):2101472. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35356152.","journal-title":"Adv Sci (Weinh)"},{"issue":"1\u20132","key":"8036_CR43","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.cell.2018.11.046","volume":"176","author":"S Gkountela","year":"2019","unstructured":"Gkountela S, Castro-Giner F, Szczerba BM, Vetter M, Landin J, Scherrer R, et al. Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. Cell. 2019;176(1\u20132):98\u2013e11214. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30633912.","journal-title":"Cell"},{"issue":"Pt 3","key":"8036_CR44","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.semcancer.2022.01.006","volume":"86","author":"X Cheng","year":"2022","unstructured":"Cheng X, Zhang H, Hamad A, Huang H, Tsung A. Surgery-mediated tumor-promoting effects on the immune microenvironment. Semin Cancer Biol. 2022;86(Pt 3):408\u201319. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35066156.","journal-title":"Semin Cancer Biol"},{"issue":"31","key":"8036_CR45","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1200\/JCO.2014.56.2561","volume":"32","author":"JB Smerage","year":"2014","unstructured":"Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol. 2014;32(31):3483\u20139. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24888818.","journal-title":"J Clin Oncol"},{"issue":"1","key":"8036_CR46","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13045-019-0813-7","volume":"12","author":"X Han","year":"2019","unstructured":"Han X, Wang Y, Wei J, Han W. Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy. J Hematol Oncol. 2019;12(1):128. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31783889.","journal-title":"J Hematol Oncol"},{"issue":"21","key":"8036_CR47","doi-asserted-by":"publisher","first-page":"9891","DOI":"10.1111\/jcmm.16939","volume":"25","author":"X Cui","year":"2021","unstructured":"Cui X, Liu R, Duan L, Cao D, Zhang Q, Zhang A. CAR-T therapy: Prospects in targeting cancer stem cells. J Cell Mol Med. 2021;25(21):9891\u2013904. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34585512.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"8036_CR48","doi-asserted-by":"publisher","first-page":"1806009","DOI":"10.1080\/2162402X.2020.1806009","volume":"9","author":"D Qin","year":"2020","unstructured":"Qin D, Li D, Zhang B, Chen Y, Liao X, Li X, et al. Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models. Oncoimmunology. 2020;9(1):1806009. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32923168.","journal-title":"Oncoimmunology"},{"issue":"2","key":"8036_CR49","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.devcel.2018.08.025","volume":"47","author":"TY Feinberg","year":"2018","unstructured":"Feinberg TY, Zheng H, Liu R, Wicha MS, Yu SM, Weiss SJ. Divergent matrix-remodeling strategies distinguish developmental from neoplastic mammary epithelial cell invasion programs. Dev Cell. 2018;47(2):145\u201360. e6. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30269950.","journal-title":"Dev Cell"},{"issue":"7","key":"8036_CR50","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.cell.2022.02.012","volume":"185","author":"RD Mazor","year":"2022","unstructured":"Mazor RD, Nathan N, Gilboa A, Stoler-Barak L, Moss L, Solomonov I, et al. Tumor-reactive antibodies evolve from non-binding and autoreactive precursors. Cell. 2022;185(7):1208\u2013e2221. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35305314.","journal-title":"Cell"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08036-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08036-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08036-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T20:02:32Z","timestamp":1784577752000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08036-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8036"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08036-x","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Human peripheral blood samples were used to construct CAR-T cells. The human blood sample collection procedure was carried out after written informed consent and approved by the Institutional Review Board at West China Hospital, Sichuan University (ID: 2022151). All animal experiments were conducted in accordance with the ARRIVE guidelines. All mouse experiments in this study were approved by the animal ethics committee of West China Hospital, Sichuan University (ID: 20240416002). All monkeys\u2019 experiments were approved by the animal ethics committee of the Kunming Institute of Zoology, Chinese Academy of Sciences (Approval ID: ACUC-PE-2024-01-005).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"424"}}